RCUS

Arcus Biosciences, Inc.
CAPPED RATING

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company which focuses on developing and commercializing cancer immunotherapies.

Arcus Biosciences, Inc. (RCUS) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.6
EV / EBITDA -4.7
Rev Growth YoY -65.4%
Gross Margin 0.0%
Price Return 3M -41.0%
Price Return 12M -12.8%
Catalyst Signal 0.00
Market Cap $2.5B
TTM Revenue $100.0M
Price / Sales 25.1
ROE -114.1%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (2.9) D (1.2) C (2.2) C (2.3) C+ (2.6) C (2.2)
2026-11-07 B- (2.9) D (1.3) C (2.2) C (2.3) C+ (2.7) C (2.3)
2026-10-31 B- (2.9) D (1.2) C (2.4) C (2.4) C+ (2.7) C (2.3)
2026-10-24 B- (2.9) D (1.2) C (2.3) C (2.4) C+ (2.6) C (2.3)
2026-10-17 B- (2.9) D (1.2) C (2.3) C+ (2.6) C+ (2.6) C (2.3)
Page 1 of 5